Industries
Cardiovascular Research and Therapeutics
Cardiovascular therapeutics address the leading cause of global mortality through lipid-lowering agents, heart failure drugs, and emerging gene-based interventions. Academic cardiovascular research groups generate foundational IP in PCSK9 biology, cardiac metabolism, and gene therapy delivery that biotech and pharma companies license for IND-enabling programs.
Details
- Companies
- Novo Nordisk CardiovascularAmgen CardiovascularEsperion TherapeuticsIonis PharmaceuticalsMyoKardia BMSTenax TherapeuticsCardurion PharmaceuticalsEditas MedicineVerve TherapeuticsStructure Therapeutics
- Market Size
- $72B
- Target Researchers
- Cardiologists, physiologists, and molecular biologists specializing in lipid metabolism, heart failure mechanisms, cardiac fibrosis, atherosclerosis, arrhythmia genetics, and gene-based cardiovascular therapies
- Use Cases
- PCSK9 and lipid metabolism target licensingHeart failure mechanism co-developmentCardiac biomarker platform partnershipsGene editing cardiovascular therapy IPPatient cohort and imaging data accessCRISPR-based cardiology program consulting